This program aims to develop CD22 × CD19 therapeutic CAR-T for B cell acute lymphoblastic leukemia (B-ALL).
Rationale for our program:
Given the above, the novel bispecific CAR targeting CD19 and CD22 we proposed might be an attractive strategy to address the recurrence of antigen escape after CD19-directed CAR-T cell therapy.
CD22 is a B cell-restricted phosphoglycoprotein of the immunoglobulin superfamily and has attracted widespread attention as a therapeutic target for B cell-directed therapy. Several novel therapeutic agents that selectively target CD22 are being developed as an alternative to B cell cancer therapy.
CD22 is expressed in almost all lymphoid malignancies. It has been reported that CD22 expression among different subtypes of ALL is 83% of Pro-B, 96.4% of normal B cells, 91.9% of Pre-B and 100% of mature B cell ALL. In several subtypes of mature B cell lymphoma, CD22 expression is reported to be higher than 90%. Therefore, CD22 can be used as a potent target for the treatment of B cell malignancies.
Fig.1 CD22 structure and signaling pathway. (Aujla, 2019)
The following data support the rationale for the development of CD22 × CD19 bispecific CAR-T cells with an improved therapeutic index in B-ALL.
Fig.2 Clinical activity and expansion of TanCAR-T 19/22 cells. (Jia, 2019)
NCT ID | Status | Sponsor | Lead Sponsor | Phase | Update Time |
NCT03241940 | Recruiting | Crystal Mackall, MD | Phase I CD19/CD22 Chimeric Antigen Receptor T Cells in Peds Recurrent/Refractory B Cell Malignancies | Phase 1 | August 29, 2019 |
NCT03448393 | Recruiting | National Cancer Institute (NCI) | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | Phase 1 | July 19, 2019 |
We have extensive knowledge of end-to-end program development. For each program, we are committed to delivering the final complete program to our clients within 1.5 years before entering the IND stage.
Creative Biolabs is looking for potential partners (include but not limit to major pharma or biotech firms) to develop CD22 × CD19 therapeutic CAR-T program together. Our scientists are dedicated to bringing years of valuable experience to our partner and achieve a meaningful partnership together. For any partners interested in our Next-IO™ programs, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from the discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate for our programs.
With our quality control protocol and knowledge of global regulatory requirements, we can help our partners further their programs with more chances to succeed. Look forward to cooperating with you in the near future.
For Research Use Only | Not For Clinical Use